ARTICLE | Finance
Abalos adds €32.5M to series A round
Funds enable German biotech to push immuno-virotherapy into clinic within next two years
October 14, 2021 6:48 PM UTC
Two years after launch, Abalos has expanded its series A round to a total of €43 million that will allow the German biotech to bring its arenavirus-based immunotherapy into the clinic.
Abalos Therapeutics GmbH said on Thursday that it raised €32.5 million ($37.7 million) in an extension of a series A round led by Seventure Partners. The biotech had previously raised €10.5 million in 2019 in a deal co-led by Boehringer Ingelheim Venture Fund and Gründerfonds Ruhr...